Prion Disease: The Implications for Dentistry

Journal of Endodontics

Volumn 34, Issue 10, 2008, Pages 1158-1166

  Azarpazhooh, Amir ^a   Fillery, Edward D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dental; dental care; infection control; prion diseases

Indexed keywords

CLASSIFICATION; CREUTZFELDT JAKOB DISEASE; DENTAL CARE; DISEASE TRANSMISSION; HUMAN; INFECTION CONTROL; INSTRUMENT STERILIZATION; METHODOLOGY; MOUTH DISEASE; PHYSIOLOGY; PRION; PRION DISEASE; REVIEW; RISK FACTOR;

CREUTZFELDT-JAKOB SYNDROME; DENTAL CARE; HUMANS; INFECTION CONTROL, DENTAL; MOUTH DISEASES; PRION DISEASES; PRIONS; RISK FACTORS; STERILIZATION;

EID: 51349161669     PISSN: 00992399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joen.2008.07.008     Document Type: Review

References (123)

1. Prusiner S.B., and McCarty M. Discovering DNA encodes heredity and prions are infectious proteins. Annu Rev Genet 40 (2006) 25-45
2. Prusiner S. Molecular biology and pathogenesis of prion diseases. Trends Biochem Sci 21 (1996) 482-487
3. Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry 76 (2005) 906
4. Schneider K., Korkmaz Y., Addicks K., Lang H., and Raab W.H. Prion protein (PrP) in human teeth: an unprecedented pointer to PrP's function. J Endod 33 (2007) 110
5. Collinge J., and Clarke A.R. A general model of prion strains and their pathogenicity. Science 318 (2007) 930-936
6. Lundmark K., Westermark G.T., Nystrom S., Murphy C.L., Solomon A., and Westermark P. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci U S A 99 (2002) 6979-6984
7. Ludlam C.A., and Turner M.L. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol 132 (2006) 13
8. Legname G., Nguyen H.O., Peretz D., Cohen F.E., DeArmond S.J., and Prusiner S.B. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc Natl Acad Sci U S A 103 (2006) 19105-19110
9. Solomon A., Richey T., Murphy C.L., et al. Amyloidogenic potential of foie gras. Proc Natl Acad Sci U S A 104 (2007) 10998-11001
10. Meyer-Luehmann M., Coomaraswamy J., Bolmont T., et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313 (2006) 1781-1784
11. Riek R. Cell biology: infectious Alzheimer's disease?. Nature 444 (2006) 429-431
12. Advisory Committee on Dangerous Pathogens Spongiform Encephalopathy. Transmissible spongiform encephalopathy agents: safe working and the prevention of infection (2003), The UK Department of Health, The Stationery Office, London
13. Belay E.D., Maddox R.A., Williams E.S., Miller M.W., Gambetti P., and Schonberger L.B. Chronic Wasting Disease and Potential Transmission to Humans. Emerg Infect Dis 10 (2004) 977-984
14. Prusiner S. Prion diseases and the BSE crisis. Science 278 (1997) 245-251
15. Bird S.M. Attributable testing for abnormal prion protein, database linkage, and blood-borne vCJD risks. Lancet 364 (2004) 1362
16. Prusiner S.B., Serban A., Koehler R., et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci U S A 90 (1993) 10608-10612
17. Brown P., and Bradley R. 1755 and all that: a historical primer of transmissible spongiform encephalopathy. BMJ 317 (1998) 1688-1692
18. Statutory Instrument. The Bovine Spongiform Encephalopathy Order 1988. http://www.opsi.gov.uk/si/si1988uksi_19881039_en_1.htm Accessed September 4, 2008.
19. Centers for Disease Control and Prevention. BSE (Bovine Spongiform Encephalopathy, or Mad Cow Disease). 2007 [updated 2007; cited 2007 July 3rd]. www.cdc.gov/ncidod/dvrd/bse/ Accessed September 4, 2008.
20. Centers for Disease Control and Prevention. vCJD (Variant Creutzfeldt-Jakob Disease). 2007 [updated 2007]. www.cdc.gov/ncidod/dvrd/vcjd/index.htm Acccessed September 4, 2008.
21. Canadian Food Inspection Agency. BSE import policy for bovine animals and their products. 2005 [updated 2005]. www.inspection.gc.ca/english/anima/heasan/policy/ie-2005-9e.shtml Acccessed September 4, 2008.
22. Belay E.D., Holman R.C., and Schonberger L.B. Creutzfeldt-Jakob disease surveillance and diagnosis. Clin Infect Dis 41 (2005) 834-836
23. Centers for Disease Control and Prevention. CJD (Creutzfeldt-Jakob Disease, Classic). 2007 [updated 2007]. www.cdc.gov/ncidod/dvrd/cjd/index.htm Acccessed September 4, 2008.
24. From the Centers for Disease Control and Prevention. Probable variant Creutzfeldt-Jakob disease in a US Resident-Florida. JAMA 288 (2002) 2965-2967
25. Will R.G., Alperovitch A., Poser S., et al. Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993-1995. EU Collaborative Study Group for CJD. Ann Neurol 43 (1998) 763-767
26. Public Health Agency of Canada. Variant Creutzfeldt-Jakob Disease (vCJD) in Canada. 2005 [updated 2005]. http://www.phac-aspc.gc.ca/cjd-mcj/vcjd-faq_e.html Acccessed September 4, 2008.
27. National Prion Disease Pathology Surveillance Center. CJD Surveillance. Cleveland]. www.cjdsurveillance.com Acccessed September 4, 2008.
28. Huillard d'Aignaux J., Cousens S.N., DelasnerieLaupretre N., et al. Analysis of the geographical distribution of sporadic Creutzfeldt-Jakob disease in France between 1992 and 1998. Int J Epidemiol 31 (2002) 490
29. Westermann G. 28th National Sterilisation Days: April 12-13, 2006, Tours, France. Zentralsterilisation Central Service 14 (2006) 166
30. Keogh P., and Flint S. Transmissible spongiform encephalopathies and dentistry. J Ir Dent Assoc 50 (2004) 160-162
31. WHO-Fact Sheet N°113. Bovine spongiform encephalopathy. 2002 [updated 2002]. www.who.int/mediacentre/factsheets/fs113/en Acccessed September 4, 2008.
32. Gill D.S., Tredwin C.J., Gill S.K., and Ironside J.W. The transmissible spongiform encephalopathies (prion diseases): a review for dental surgeons. Int Dent J 51 (2001) 439
33. Ena J. Prions: who should worry about them?. Arch Med Res 36 (2005) 622
34. Brown P., Preece M., Brandel J.P., et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 55 (2000) 1075
35. Will R. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 66 (2003) 255-265
36. Llewelyn C., Hewitt P., Knight R., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363 (2004) 417-421
37. Gajdusek D., and Zigas V. Degenerative disease of the central nervous system in New Guinea: epidemic of 'Kuru' in the native population. N Engl J Med 257 (1957) 974-978
38. Porter S., Scully C., Ridgway G., and Bell J. The human transmissible spongiform encephalopathies (TSEs): implications for dental practitioners. Br Dent J 188 (2000) 432-436
39. Will R.G., Ironside J.W., Zeidler M., et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347 (1996) 921-925
40. Alperovitch A., Zerr I., Pocchiari M., et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 353 (1999) 1673
41. Lasmezas C.I., Deslys J.P., Demaimay R., et al. BSE transmission to macaques. Nature 381 (1996) 743-744
42. Collinge J., Sidle K.C., Meads J., Ironside J., and Hill A.F. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 383 (1996) 685-690
43. Bruce M.E., Will R.G., Ironside J.W., et al. Transmissions to mice indicate that 'variant' CJD is caused by the BSE agent. Nature 389 (1997) 498-501
44. Scott M.R., Will R., Ironside J., et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci U S A 96 (1999) 15137-15142
45. Ward H.J., Everington D., Cousens S.N., et al. Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. Ann Neurol 59 (2006) 111-120
46. Hilton D.A., Ghani A.C., Conyers L., et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 203 (2004) 733-739
47. Porter S.R. Prion disease: possible implications for oral health care. see comment. J Am Dent Assoc 134 (2003) 1486
48. Zeidler M., Johnstone E.C., Bamber R.K., et al. New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet 350 (1997) 908
49. Reuber M., Al-Din A.S.N., Baborie A., and Chakrabarty A. New variant Creutzfeldt-Jakob disease presenting with loss of taste and smell. J Neurol Neurosurg Psychiatry 71 (2001) 412-413
50. Spongiform Encephalopathy Advisory Committee (SEAC). vCJD and Dentistry. 2007 [updated 2007]. www.seac.gov.uk/statements/state-vcjd-dentrstry.htm Acccessed September 4, 2008.
51. Economics and Operational Research Division (EOR4). Risk Assessment for vCJD and Dentistry (2003), The UK Department of Health, London
52. Trifilo M.J., Ying G., Teng C., and Oldstone M.B. Chronic wasting disease of deer and elk in transgenic mice: oral transmission and pathobiology. Virology 365 (2007) 136-143
53. DeJoia C., Moreaux B., O'Connell K., and Bessen R.A. Prion infection of oral and nasal mucosa. J Virol 80 (2006) 4546-4556
54. Sc in the skeletal muscle of patients with variant, iatrogenic, and sporadic forms of Creutzfeldt-Jakob disease. Am J Pathol 168 (2006) 927-935
55. Malmstrom M., and Husby G. Occurrence of amyloid in the teeth-supporting tissues of patients with rheumatoid diseases. An immunohistochemical study. Scand J Rheumatol 4 (1975) 186-192
56. In: Delves P., Martin S., Burton D., and Roitt I. (Eds). Roitt's Essential Immunology. 11th ed. (2006), Blackwell Publishing, London
57. Bebermeyer R.D., Powell J.F., Hobdell M.H., and Durban E.M. Dental practice implications of prion diseases. Quintessence Int 34 (2003) 38
58. Smith A.J., Russell D.I., Greene J., Lowman A., and Ironside J.W. Presentation of a case of variant CJD in general dental practice. Br Dent J 197 (2004) 75
59. Zeidler M., Sellar R.J., Collie D.A., et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfetdt-Jakob disease. Lancet 355 (2000) 1412-1418
60. Hsich G., Kenney K., Gibbs C.J., Lee K.H., and Harrington M.G. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 335 (1996) 924-930
61. Hill A.F., Butterworth R.J., Joiner S., et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 353 (1999) 183
62. Sanchez-Juan P., Green A., Ladogana A., et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 67 (2006) 637-643
63. Scully C., Smith A.J., and Bagg J. Prions and the human transmissible spongiform encephalopathies. Dent Clin North Am 47 (2003) 493
64. Lipscomb I.P., Herve R., Harris K., Pinchin H., Collin R., and Keevil C.W. Amyloid-specific fluorophores for the rapid, sensitive in situ detection of prion contamination on surgical instruments. J Gen Virol 88 (2007) 2619-2626
65. Ishikawa K., Doh-ura K., Kudo Y., et al. Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J Gen Virol 85 (2004) 1785-1790
66. Health Canada Online. Blood Safety and Variant Creutzfeldt-Jakob Disease (Variant CJD). 2003 [updated 2003]. www.hc-sc.gc.ca/english/diseases/cjd/bg7.html Acccessed September 4, 2008.
67. UK Department of Health. Blood transfusion incident involving vCJD. 2003 [updated 2003]. www.info.doh.gov.uk/doh/embroadcast.nsf/vwDiscussionAll/0301ECC6DF485EF880256DFF004DA063 Acccessed September 4, 2008.
68. Peden A., Head M., Ritchie D., Bell J., and Ironside J. Pre-clinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364 (2004) 527-529
69. Hewitt P.E., Llewelyn C.A., Mackenzie J., and Will R.G. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 91 (2006) 221-230
70. Huang F.P., and MacPherson G.G. Dendritic cells and oral transmission of prion diseases. Adv Drug Deliv Rev 56 (2004) 901-913
71. Dyer O. Hospitals to spend 200m pounds sterling to prevent spread of vCJD. BMJ 322 (2001) 68
72. Baier M., Norley S., Schultz J., Burwinkel M., Schwarz A., and Riemer C. Prion diseases: infectious and lethal doses following oral challenge. J Gen Virol 84 (2003) 1927-1929
73. Canadian Blood Services. Deferral Policies for vCJD. Ottawa; 2007 [updated 2007]. www.bloodservices.ca/centreapps/internet/uw_v502_mainengine.nsf/page/Deferral%20Policies%20for%20vCJD?OpenDocument Acccessed September 4, 2008.
74. Spongiform Encephalopathy Advisory Committee. The 98th Meeting of SEAC webcast; 2007. http://clients.westminster_digital.co.uk/seac/98thmeeting/ Accessed September 4, 2008.
75. WHO consultation. WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies (1999), World Health Organization Communicable Disease Surveillance and Control, Geneva, Switzerland Report No.: WHO/CDS/CSR/APH/2000.
76. Berger J.R., and David N.J. Creutzfeldt-Jakob disease in a physician: a review of the disorder in health care workers. Neurology 43 (1993) 205
77. Wientjens D.P., Davanipour Z., Hofman A., et al. Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology 46 (1996) 1287-1291
78. Public Health Leadership Society. Investigation of geographically associated cases of variant CJD in north east England. Commun Dis Rep CDR Wkly 12 (2002) 3-4
79. Will R.G., and Matthews W.B. Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 45 (1982) 235
80. Arakawa K., Nagara H., Itoyama Y., et al. Clustering of three cases of Creutzfeldt-Jakob disease near Fukuoka City, Japan. Acta Neurol Scand 84 (1991) 445
81. Adams D., and Edgar W. Transmission of agent of Creutzfeldt-Jakob disease. Br Med J 1 (1978) 987
82. Collins S., Law M., Fletcher A., Boyd A., Kaldor J., and Masters C. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 353 (1999) 693-697
83. Davanipour Z., Alter M., Sobel E., Asher D., and Gajdusek D.C. Creutzfeldt-Jakob disease-possible medical risk factors. Neurology 35 (1985) 1483-1486
84. Kondo K., and Kuroiwa Y. A case control study of Creutzfeldt-Jakob disease: association with physical injuries. Ann Neurol 11 (1982) 377-381
85. van Duijn C., Delasnerie-Laupretre N., Masullo C., et al. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet 35 (1998) 1081-1085
86. Zerr I., Brandel J.-P., Masullo C., et al. European surveillance on Creutzfeldt-Jakob disease: a case-control study for medical risk factors. J Clin Epidemiol 53 (2000) 747
87. Harries-Jones R., Knight R., Will R.G., Cousens S., Smith P.G., and Matthews W.B. Creutzfeldt-Jakob disease in England and Wales, 1980-1984: a case-control study of potential risk factors. J Neurol Neurosurg Psychiatry 51 (1988) 1113-1119
88. Everington D., Smith A.J., Ward H.J., Letters S., and Will R.G. Dental treatment and risk of variant CJD-a case control study. Br Dent J 28 (2007) E19
89. Blanquet-Grossard F., Sazdovitch V., Jean A., et al. Prion protein is not detectable in dental pulp from patients with Creutzfeldt-Jakob disease. J Dent Res 79 (2000) 700
90. Spongiform Encephalopathy Advisory Committee (SEAC). Position statement vCJD and Endodontic dentistry. 2006 [updated 2006]. www.seac.gov.uk/statements/statement0506.htm Acccessed September 4, 2008.
91. Bourvis N., Boelle P.Y., Cesbron J.Y., and Valleron A.J. Risk assessment of transmission of sporadic Creutzfeldt-Jakob disease in endodontic practice in absence of adequate prion inactivation. PLoS ONE 2 (2007) e1330
92. res in dental tissues in variant CJD. Br Dent J 195 (2003) 339
93. Carp R. Transmission of scrapie by oral route: effect of gingival scarification. Lancet 1 (1982) 170-171
94. Ingrosso L., Pisani F., and Pocchiari M. Transmission of the 263K scrapie strain by the dental route. J Gen Virol 80 (1999) 3043
95. Wells G.A.H., Hawkins S.A.C., Green R.B., et al. Preliminary observations on the pathogenesis of experimental bovine spongiform encephalopathy (BSE): an update. Vet Rec 142 (1998) 103-106
96. Groschup M.H., Beekes M., McBride P.A., Hardt M., Hainfellner J.A., and Budka H. Deposition of disease-associated prion protein involves the peripheral nervous system in experimental scrapie. Acta Neuropathol (Berl) 98 (1999) 453-457
97. Bartz J.C., Kincaid A.E., and Bessen R.A. Rapid prion neuroinvasion following tongue infection. J Virol 77 (2003) 583-591
98. Sakaguchi S., Katamine S., Yamanouchi K., et al. Kinetics of infectivity are dissociated from PrP accumulation in salivary glands of Creutzfeldt-Jakob disease agent-inoculated mice. J Gen Virol 74 (1993) 2117-2123
99. Pattison I.H., and Millson G.C. Distribution of the scrapie agent in the tissues of experimentally inoculated goats. J Comp Pathol 72 (1962) 233-244
100. Eklund C.M., Kennedy R.C., and Hadlow W.J. Pathogenesis of scrapie virus infection in the mouse. J Infect Dis 117 (1967) 15-22
101. Scottish Dental Clinical Effectiveness Programme. Decontamination Into Practice - Cleaning of Dental Instruments The National Dental Advisory Committee (NDAC), the Scottish Executive and NHS Education for Scotland; 2007. Report No.: 978 1 905829 03 3.
102. Letters S., Smith A.J., McHugh S., and Bagg J. A study of visual and blood contamination on reprocessed endodontic files from general dental practice. Br Dent J 199 (2005) 522-525
103. Smith A., Letters S., Lange A., Perrett D., McHugh S., and Bagg J. Residual protein levels on reprocessed dental instruments. J Hosp Infect (2005) 61-:237
104. Smith A., Dickson M., Aitken J., and Bagg J. Contaminated dental instruments. J Hosp Infect 51 (2002) 233
105. Parirokh M., Asgary S., and Eghbal M.J. An energy-dispersive X-ray analysis and SEM study of debris remaining on endodontic instruments after ultrasonic cleaning and autoclave sterilization. Aust Endod J 31 (2005) 53-58
106. Coulter W. Cleaning re-usable instruments in general practice. Br Dent J 202 (2007) 550
107. Linsuwanont P., Parashos P., and Messer H.H. Cleaning of rotary nickel-titanium endodontic instruments. Int Endod J 37 (2004) 19-28
108. Sonntag D., and Peters O.A. Effect of prion decontamination protocols on nickel-titanium rotary surfaces. J Endod 33 (2007) 442-446
109. Walker J.T., Dickinson J., Sutton J.M., Raven N.D., and Marsh P.D. Cleanability of dental instruments-implications of residual protein and risks from Creutzfeldt-Jakob disease. Br Dent J 203 (2007) 395-401
110. Canada Communicable Disease Report. Infection Control Guidelines: Classic Creutzfeldt-Jakob Disease in Canada: Nosocomial and Occupational Infections, Health Care Acquired Infections Division (2002), Centre for Infectious Disease Prevention and Control Population and Public Health Branch, Health Canada, Ottawa, Canada
111. Hamilton J. Prions: transmissible spongiform encephalopathies and dental transmission risk assessment. J Calif Dent Assoc 35 (2007) 30
112. Fédération Dentaire Internationale. FDI policy statement on transmissible spongiform encephalopathies: implications for the practice of dentistry [updated 2001, reconfirmed October 2007]. www.fdiworldental.org/federation/assets/statements/ENGLISH/2007/TSE_2007.pdf Acccessed September 4, 2008.
113. Brown P., Liberski P.P., Wolff A., and Gajdusek D.C. Resistance of scrapie infectivity to steam autoclaving after formaldehyde fixation and limited survival after ashing at 360 degrees C: practical and theoretical implications. J Infect Dis 161 (1990) 467-472
114. Brown S.A., and Merritt K. Use of containment pans and lids for autoclaving caustic solutions. Am J Infect Control 31 (2003) 257
115. Peretz D., Supattapone S., Giles K., et al. Inactivation of prions by acidic sodium dodecyl sulfate. J Virol 80 (2006) 322-331
116. Whitworth C.L., Davies K., Palmer N.O., and Martin M.V. An investigation of the decontamination of Siqveland matrix bands. Br Dent J 202 (2007) E12
117. Lowe A.H., Bagg J., Burke F.J., MacKenzie D., and McHugh S. A study of blood contamination of Siqveland matrix bands. Br Dent J 192 (2002) 43-45
118. Whitworth C.L., Martin M.V., Gallagher M., and Worthington H.V. A comparison of decontamination methods used for dental burs. Br Dent J 197 (2004) 635-640
119. Parashos P., Linsuwanont P., and Messer H.H. A cleaning protocol for rotary nickel-titanium endodontic instruments. Aust Dent J 49 (2004) 20-27
120. Centers for Disease Control and Prevention. Guidelines for Infection Control in Dental Health-Care Settings. MMWR Morb Mortal Wky Rep 52 (2003) 2003
121. UK Department of Health. Precautionary advice given to dentists on re-use of instruments. 2007 [updated 2007]. www.gnn.gov.uk/environment/fullDetail.asp?ReleaseID=279256&NewsAreaID=2&Navig Acccessed September 4, 2008.
122. Australian Government Department of Health and Ageing. Infection control guidelines for the prevention of transmission of infectious diseases in the health care setting. Part 4 Managing Infectious Diseases in the Health Care Setting; 2007. Revised version as of December 2007. http://www.health.gov.au/internet/main/publishing.nsf/content/2804E9F9B95357F7CA256F190003B4DA/$File/goodCJD%20Chapter%2031.pdf Accessed September 4, 2008.
123. Smith A.J., Bagg J., Ironside J.W., Will R.G., and Scully C. Prions and the oral cavity. J Dent Res 82 (2003) 769